AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 76_CD Form_NN 20-F_JJ Information_NN 2004_CD Accounting_NNP Policies_NNS Basis_NN of_IN accounting_NN calculated_VBN after_IN charging_VBG the_DT gross_JJ amount_NN ,_, currency_NN loans_NNS ,_, are_VBP taken_VBN to_TO operating_VBG profit_NN ._.
The_DT Financial_NNP Statements_NNP are_VBP prepared_VBN under_IN at_IN current_JJ exchange_NN rates_NNS ,_, of_IN any_DT such_JJ In_IN the_DT consolidated_JJ Financial_NNP Statements_NNP ,_, the_DT historical_JJ cost_NN convention_NN ,_, modified_VBN to_TO goodwill_NN ._.
exchange_NN differences_NNS arising_VBG on_IN include_VBP the_DT revaluation_NN to_TO market_NN value_NN of_IN consolidation_NN of_IN the_DT net_JJ investments_NNS in_IN certain_JJ current_JJ asset_NN investments_NNS held_VBN by_IN Intangible_JJ assets_NNS ,_, including_VBG patents_NNS acquired_VBN ,_, subsidiaries_NNS ,_, joint_JJ ventures_NNS and_CC associates_NNS ,_, Group_NNP subsidiaries_NNS as_IN described_VBN below_IN ,_, in_IN are_VBP capitalized_VBN and_CC amortised_VBN over_IN their_PRP$ together_RB with_IN those_DT on_IN relevant_JJ foreign_JJ accordance_NN with_IN the_DT Companies_NNS Act_NNP 1985_CD estimated_VBD useful_JJ lives_NNS generally_RB not_RB currency_NN loans_NNS ,_, are_VBP taken_VBN directly_RB to_TO reserves_NNS and_CC UK_NNP generally_RB accepted_VBD accounting_NN exceeding_VBG 20_CD years_NNS ,_, in_IN line_NN with_IN the_DT benefits_NNS via_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS principles_NNS UK_NNP GAAP_NNP ._.
If_IN related_JJ products_NNS fail_VBP ,_, the_DT and_CC losses_NNS ._.
significant_JJ differences_NNS to_TO US_NNP GAAP_NNP these_DT remaining_VBG unamortised_JJ amounts_NNS are_VBP have_VBP been_VBN described_VBN in_IN the_DT US_NNP GAAP_NNP immediately_RB written_VBD off_RP to_TO revenue_NN expense_NN ._.
Taxation_NNP section_NN on_IN pages_NNS 125_CD to_TO 135_CD ._.
The_DT following_JJ Finance_NNP costs_NNS and_CC internally_RB developed_VBD The_DT charge_NN for_IN taxation_NN is_VBZ based_VBN on_IN the_DT profit_NN paragraphs_NNS describe_VBP the_DT main_JJ accounting_NN intangible_JJ assets_NNS are_VBP not_RB capitalized_VBN ._.
All_DT for_IN the_DT year_NN and_CC takes_VBZ into_IN account_NN taxation_NN policies_NNS under_IN UK_NNP GAAP_NNP ,_, which_WDT have_VBP been_VBN intangible_JJ assets_NNS are_VBP reviewed_VBN for_IN impairment_NN deferred_VBN because_IN of_IN timing_NN differences_NNS applied_VBD consistently_RB ._.
The_DT accounting_NN policies_NNS when_WRB there_EX are_VBP indications_NNS that_IN the_DT carrying_VBG between_IN the_DT treatment_NN of_IN certain_JJ items_NNS of_IN some_DT overseas_JJ subsidiaries_NNS and_CC value_NN may_MD not_RB be_VB recoverable_JJ ._.
for_IN taxation_NN and_CC for_IN accounting_NN purposes_NNS ._.
associated_VBN undertakings_NNS do_VBP not_RB conform_VB Full_NNP provision_NN is_VBZ made_VBN for_IN the_DT effects_NNS of_IN these_DT with_IN UK_NNP GAAP_NNP and_CC ,_, where_WRB appropriate_JJ ,_, Post-retirement_JJ benefits_NNS differences_NNS ._.
Deferred_JJ tax_NN asset_NN valuation_NN adjustments_NNS are_VBP made_VBN on_IN consolidation_NN The_DT pension_NN costs_NNS relating_VBG to_TO UK_NNP retirement_NN allowances_NNS are_VBP made_VBN where_WRB it_PRP is_VBZ more_RBR likely_JJ in_IN order_NN to_TO present_VB the_DT Group_NNP Financial_NNP plans_NNS are_VBP assessed_VBN in_IN accordance_NN with_IN the_DT than_IN not_RB that_IN the_DT asset_NN will_MD not_RB be_VB realized_VBN Statements_NNS on_IN a_DT consistent_JJ basis_NN ._.
advice_NN of_IN independent_JJ qualified_JJ actuaries_NNS ._.
These_DT valuations_NNS require_VBP The_DT amounts_NNS so_IN determined_JJ include_VBP the_DT judgements_NNS to_TO be_VB made_VBN including_VBG the_DT AstraZenecas_NNP management_NN considers_VBZ regular_JJ cost_NN of_IN providing_VBG the_DT benefits_NNS under_IN forecast_NN of_IN future_JJ taxable_JJ income_NN ._.
Deferred_VBN the_DT following_VBG to_TO be_VB the_DT most_RBS important_JJ the_DT plans_NNS ,_, which_WDT it_PRP is_VBZ intended_VBN should_MD remain_VB tax_NN balances_NNS are_VBP not_RB discounted_VBN ._.
accounting_NN policies_NNS in_IN the_DT context_NN of_IN the_DT as_IN a_DT level_NN percentage_NN of_IN current_JJ and_CC Groups_NNS operations_NNS ._.
expected_JJ future_JJ earnings_NNS of_IN the_DT employees_NNS Accruals_NNP for_IN tax_NN contingencies_NNS require_VBP covered_VBN under_IN the_DT plans_NNS ._.
Variations_NNS from_IN the_DT management_NN to_TO make_VB judgements_NNS and_CC Turnover_NN regular_JJ pension_NN cost_NN are_VBP spread_VBN on_IN a_DT estimates_NNS in_IN relation_NN to_TO tax_NN audit_NN issues_NNS and_CC Turnover_NN excludes_VBZ intercompany_NN turnover_NN systematic_JJ basis_NN over_IN the_DT estimated_VBN average_JJ exposures_NNS ._.
Tax_NNP benefits_NNS are_VBP not_RB recognized_VBN and_CC value_NN added_VBD taxes_NNS and_CC represents_VBZ net_JJ remaining_VBG service_NN lives_NNS of_IN current_JJ employees_NNS unless_IN the_DT tax_NN positions_NNS will_MD probably_RB be_VB invoice_JJ value_NN less_RBR estimated_JJ rebates_NNS ,_, returns_NNS in_IN the_DT plans_NNS ._.
Retirement_NNP plans_NNS of_IN non-UK_JJ sustained_VBN ._.
Once_RB considered_VBN to_TO be_VB probable_JJ ,_, and_CC settlement_NN discounts_NNS ._.
Revenue_NN is_VBZ subsidiaries_NNS are_VBP accounted_VBN for_IN in_IN accordance_NN management_NN reviews_VBZ each_DT material_NN tax_NN recognized_VBN at_IN the_DT point_NN at_IN which_WDT title_NN passes_VBZ ._.
with_IN local_JJ conditions_NNS and_CC practice_NN ._.
With_IN benefit_NN to_TO assess_VB whether_IN a_DT provision_NN should_MD minor_JJ exceptions_NNS ,_, these_DT subsidiaries_NNS be_VB taken_VBN against_IN full_JJ recognition_NN of_IN that_DT Research_NNP and_CC development_NN recognize_VBP the_DT expected_VBN cost_NN of_IN providing_VBG benefit_NN on_IN the_DT basis_NN of_IN potential_JJ settlement_NN Internally_RB generated_VBD research_NN and_CC pensions_NNS on_IN a_DT systematic_JJ basis_NN over_IN the_DT through_IN negotiation_NN and_CC or_CC litigation_NN ._.
development_NN expenditure_NN is_VBZ charged_VBN average_JJ remaining_VBG service_NN lives_NNS of_IN employees_NNS to_TO profit_VB in_IN the_DT year_NN in_IN which_WDT it_PRP is_VBZ incurred_VBN ._.
in_IN accordance_NN with_IN the_DT advice_NN of_IN Any_DT recorded_VBN exposure_NN to_TO interest_NN on_IN tax_NN independent_JJ qualified_JJ actuaries_NNS ._.
The_DT costs_NNS of_IN liabilities_NNS is_VBZ provided_VBN for_IN in_IN the_DT tax_NN charge_NN ._.
Goodwill_NN and_CC intangible_JJ assets_NNS providing_VBG post-retirement_JJ benefits_NNS other_JJ than_IN All_DT provisions_NNS are_VBP included_VBN in_IN creditors_NNS due_JJ On_IN the_DT acquisition_NN of_IN a_DT business_NN ,_, fair_JJ values_NNS pensions_NNS principally_RB healthcare_NN are_VBP charged_VBN within_IN one_CD year_NN ._.
are_VBP attributed_VBN to_TO the_DT net_JJ assets_NNS acquired_VBN ._.
to_TO the_DT profit_NN and_CC loss_NN account_NN on_IN a_DT consistent_JJ Goodwill_NNP arises_VBZ where_WRB the_DT fair_JJ value_NN of_IN the_DT basis_NN over_IN the_DT average_JJ service_NN lives_NNS of_IN No_DT provision_NN is_VBZ made_VBN for_IN unremitted_JJ earnings_NNS consideration_NN given_VBN for_IN a_DT business_NN exceeds_VBZ employees_NNS ._.
Such_JJ costs_NNS are_VBP assessed_VBN in_IN of_IN foreign_JJ subsidiaries_NNS where_WRB there_EX is_VBZ no_DT the_DT fair_JJ value_NN of_IN such_JJ net_JJ assets_NNS ._.
Goodwill_NN accordance_NN with_IN the_DT advice_NN of_IN independent_JJ commitment_NN to_TO remit_VB such_JJ earnings_NNS and_CC arising_VBG on_IN acquisitions_NNS since_IN 1998_CD is_VBZ qualified_VBN actuaries_NNS ._.
AstraZeneca_NNP has_VBZ adopted_VBN where_WRB there_EX is_VBZ a_DT plan_NN to_TO permanently_RB reinvest_VB capitalized_JJ and_CC amortised_JJ over_IN its_PRP$ estimated_VBN the_DT disclosure_NN requirements_NNS of_IN FRS_NNP 17_CD ._.
such_JJ earnings_NNS ._.
No_DT provision_NN is_VBZ made_VBN for_IN useful_JJ life_NN generally_RB not_RB exceeding_VBG 20_CD years_NNS ._.
Goodwill_NN is_VBZ reviewed_VBN for_IN impairment_NN when_WRB Foreign_NNP currencies_NNS there_EX are_VBP indications_NNS that_IN the_DT carrying_VBG value_NN Profit_NN and_CC loss_NN accounts_NNS in_IN foreign_JJ currencies_NNS Tangible_JJ fixed_VBN assets_NNS may_MD not_RB be_VB recoverable_JJ ._.
The_DT Groups_NNS policy_NN are_VBP translated_VBN into_IN US_NNP dollars_NNS at_IN average_JJ AstraZenecas_NNPS policy_NN is_VBZ to_TO write_VB off_RP the_DT up_RB to_TO and_CC including_VBG 1997_CD was_VBD to_TO eliminate_VB rates_NNS for_IN the_DT relevant_JJ accounting_NN periods_NNS ._.
difference_NN between_IN the_DT cost_NN of_IN each_DT tangible_JJ goodwill_NN arising_VBG upon_IN acquisitions_NNS against_IN Assets_NNS and_CC liabilities_NNS are_VBP translated_VBN at_IN fixed_JJ asset_NN in_IN use_NN and_CC its_PRP$ residual_JJ value_NN evenly_RB reserves_NNS ._.
Such_JJ goodwill_NN will_MD remain_VB exchange_NN rates_NNS prevailing_VBG at_IN the_DT date_NN of_IN the_DT over_IN its_PRP$ estimated_VBN remaining_VBG life_NN ._.
Assets_NNS eliminated_VBN against_IN reserves_NNS until_IN disposal_NN Group_NNP balance_NN sheet_NN ._.
under_IN construction_NN are_VBP not_RB depreciated_VBN ._.
or_CC termination_NN of_IN the_DT previously_RB acquired_VBN Reviews_NNS are_VBP made_VBN periodically_RB of_IN the_DT business_NN including_VBG the_DT planned_VBN disposal_NN Exchange_NN gains_NNS and_CC losses_NNS on_IN short_JJ term_NN estimated_VBN remaining_VBG lives_NNS of_IN individual_JJ or_CC termination_NN when_WRB there_EX are_VBP indications_NNS foreign_JJ currency_NN borrowings_NNS and_CC deposits_NNS productive_JJ assets_NNS ,_, taking_VBG account_NN of_IN that_IN the_DT value_NN of_IN the_DT goodwill_NN has_VBZ been_VBN are_VBP included_VBN within_IN net_JJ interest_NN payable_JJ ._.
commercial_JJ and_CC technological_JJ obsolescence_NN permanently_RB impaired_VBN ,_, when_WRB the_DT profit_NN Exchange_NNP differences_NNS on_IN all_DT other_JJ as_RB well_RB as_IN normal_JJ wear_NN and_CC tear_VB ._.
Under_IN this_DT or_CC loss_NN on_IN disposal_NN or_CC termination_NN will_MD be_VB transactions_NNS ,_, except_IN relevant_JJ foreign_JJ policy_NN it_PRP becomes_VBZ impracticable_JJ to_TO calculate_VB AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 77_CD average_JJ asset_NN lives_VBZ exactly_RB ._.
However_RB ,_, the_DT Current_JJ asset_NN investments_NNS held_VBN by_IN the_DT total_JJ lives_NNS range_VBP from_IN approximately_RB 13_CD to_TO 50_CD Groups_NNS insurance_NN company_NN subsidiaries_NNS ,_, years_NNS for_IN buildings_NNS ,_, and_CC three_CD to_TO 15_CD years_NNS for_IN to_TO the_DT extent_NN that_IN they_PRP are_VBP actively_RB matched_VBN plant_NN and_CC equipment_NN ._.
All_DT tangible_JJ fixed_JJ assets_NNS against_IN insurance_NN liabilities_NNS ,_, are_VBP valued_VBN at_IN are_VBP reviewed_VBN for_IN impairment_NN when_WRB there_EX are_VBP market_NN value_NN and_CC unrealised_JJ gains_NNS and_CC losses_NNS indications_NNS that_IN the_DT carrying_VBG value_NN may_MD not_RB are_VBP taken_VBN directly_RB to_TO reserves_NNS via_IN the_DT be_VB recoverable_JJ ._.
statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS ._.
Realised_VBN gains_NNS and_CC losses_NNS are_VBP taken_VBN Leases_NNS to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
Assets_NNS held_VBN under_IN finance_NN leases_NNS are_VBP capitalized_VBN and_CC included_VBN in_IN tangible_JJ fixed_VBN Contingent_NNP liabilities_NNS assets_NNS at_IN fair_JJ value_NN ._.
Each_DT asset_NN is_VBZ depreciated_VBN Through_IN the_DT normal_JJ course_NN of_IN business_NN ,_, over_IN the_DT shorter_JJR of_IN the_DT lease_NN term_NN or_CC its_PRP$ useful_JJ AstraZeneca_NNP is_VBZ involved_VBN in_IN legal_JJ disputes_NNS ,_, life_NN ._.
The_DT obligations_NNS related_VBN to_TO finance_VB leases_NNS ,_, the_DT settlement_NN of_IN which_WDT may_MD involve_VB cost_NN net_NN of_IN finance_NN charges_NNS in_IN respect_NN of_IN future_NN to_TO the_DT Group_NNP ._.
Provision_NNP is_VBZ made_VBN where_WRB an_DT periods_NNS ,_, are_VBP included_VBN ,_, as_IN appropriate_JJ ,_, adverse_JJ outcome_NN is_VBZ probable_JJ and_CC associated_VBN under_IN creditors_NNS due_JJ within_IN ,_, or_CC creditors_NNS due_JJ costs_NNS can_MD be_VB estimated_VBN reliably_RB ._.
The_DT interest_NN element_NN of_IN the_DT rental_JJ obligation_NN is_VBZ allocated_VBN to_TO accounting_VBG AstraZeneca_NNP is_VBZ exposed_VBN to_TO environmental_JJ periods_NNS during_IN the_DT lease_NN term_NN to_TO reflect_VB a_DT liabilities_NNS relating_VBG to_TO its_PRP$ past_JJ operations_NNS ,_, constant_JJ rate_NN of_IN interest_NN on_IN the_DT remaining_VBG principally_RB in_IN respect_NN of_IN soil_NN and_CC groundwater_NN balance_NN of_IN the_DT obligation_NN for_IN each_DT accounting_NN remediation_NN costs_NNS ._.
Provisions_NNS for_IN these_DT costs_NNS period_NN ._.
Rentals_NNS under_IN operating_VBG leases_NNS are_VBP are_VBP made_VBN when_WRB there_EX is_VBZ a_DT present_JJ obligation_NN ,_, charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN as_IN it_PRP is_VBZ probable_JJ that_IN expenditure_NN on_IN remedial_JJ incurred_VBN ._.
work_NN will_MD be_VB required_VBN and_CC a_DT reliable_JJ estimate_NN can_MD be_VB made_VBN of_IN the_DT cost_NN ._.
Investments_NNP An_DT associate_NN is_VBZ an_DT undertaking_NN ,_, not_RB being_VBG Stock_NNP valuation_NN a_DT subsidiary_NN or_CC joint_JJ venture_NN ,_, in_IN which_WDT Stocks_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN or_CC net_JJ AstraZeneca_NNP has_VBZ a_DT participating_VBG interest_NN and_CC realisable_JJ value_NN ._.
The_DT first_JJ in_IN ,_, first_RB out_IN or_CC an_DT over_IN whose_WP$ commercial_JJ and_CC financial_JJ policy_NN average_NN method_NN of_IN valuation_NN is_VBZ used_VBN ._.
In_IN decisions_NNS AstraZeneca_NNP exercises_VBZ significant_JJ determining_VBG cost_NN ,_, depreciation_NN is_VBZ included_VBN influence_NN ._.
but_CC selling_VBG expenses_NNS and_CC certain_JJ overhead_NN expenses_NNS principally_RB central_JJ administration_NN A_DT joint_JJ venture_NN is_VBZ an_DT entity_NN in_IN which_WDT costs_NNS are_VBP excluded_VBN ._.
Net_JJ realisable_JJ value_NN is_VBZ AstraZeneca_NNP holds_VBZ an_DT interest_NN on_IN a_DT long_JJ term_NN determined_VBD as_IN estimated_VBN selling_NN price_NN less_RBR basis_NN and_CC which_WDT is_VBZ jointly_RB controlled_VBN by_IN costs_NNS of_IN disposal_NN ._.
AstraZeneca_NNP and_CC one_CD or_CC more_JJR other_JJ venturers_NNS under_IN a_DT contractual_JJ arrangement_NN ._.
Principal_NN financial_JJ instruments_NNS Forward_RB foreign_JJ exchange_NN contracts_NNS for_IN AstraZenecas_NNP share_NN of_IN the_DT profits_NNS less_RBR losses_NNS existing_VBG transactions_NNS are_VBP revalued_VBN to_TO year_NN of_IN all_DT significant_JJ joint_JJ ventures_NNS and_CC associates_NNS end_VBP spot_NN rates_NNS and_CC the_DT gains_NNS losses_NNS arising_VBG is_VBZ included_VBN in_IN the_DT Group_NNP profit_NN and_CC loss_NN are_VBP recognized_VBN in_IN the_DT Group_NNP profit_NN and_CC loss_NN account_NN on_IN the_DT equity_NN accounting_NN basis_NN or_CC ,_, account_NN ._.
Interest_NN differentials_NNS are_VBP amortised_VBN in_IN the_DT case_NN of_IN joint_JJ ventures_NNS ,_, the_DT gross_JJ equity_NN on_IN a_DT straight_JJ line_NN basis_NN over_IN the_DT life_NN of_IN the_DT accounting_NN basis_NN ._.
The_DT holding_NN value_NN of_IN contract_NN ._.
significant_JJ associates_NNS and_CC joint_JJ ventures_NNS in_IN the_DT Group_NNP balance_NN sheet_NN is_VBZ calculated_VBN by_IN The_DT gains_NNS losses_NNS on_IN forward_RB foreign_JJ reference_NN to_TO AstraZenecas_NNP equity_NN in_IN the_DT net_JJ exchange_NN contracts_NNS and_CC currency_NN option_NN assets_NNS of_IN such_JJ associates_NNS and_CC joint_JJ ventures_NNS ,_, contracts_NNS hedging_VBG anticipated_JJ exposures_NNS as_IN shown_VBN by_IN the_DT most_RBS recent_JJ accounts_NNS are_VBP deferred_VBN until_IN the_DT date_NN the_DT underlying_VBG available_JJ ,_, adjusted_VBN where_WRB appropriate_JJ and_CC transaction_NN being_VBG hedged_VBN is_VBZ completed_VBN ._.
including_VBG goodwill_NN on_IN acquisitions_NNS made_VBN since_IN 1_CD January_NNP 1998_CD ._.
Interest_NN rate_NN swaps_NNS are_VBP accounted_VBN for_IN on_IN an_DT accruals_NNS basis_NN ._.
Cross-currency_NN swaps_NNS Fixed_VBN asset_NN investments_NNS are_VBP stated_VBN at_IN cost_NN are_VBP translated_VBN at_IN year_NN end_NN exchange_NN rates_NNS :_: and_CC reviewed_VBN for_IN impairment_NN if_IN there_EX are_VBP gains_NNS losses_NNS arising_VBG are_VBP included_VBN in_IN the_DT indications_NNS that_IN the_DT carrying_VBG value_NN may_MD not_RB measurement_NN of_IN the_DT related_JJ liabilities_NNS and_CC be_VB recoverable_JJ ._.
dealt_VBN with_IN in_IN the_DT Group_NNP profit_NN and_CC loss_NN account_NN or_CC reserves_NNS as_IN appropriate_JJ ._.
